Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 2Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 42Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Lymphoma 3Breast Diseases 3Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Liposarcoma 2Hematologic Neoplasms 2Glioma 2Carcinoma, Renal Cell 2Breast Neoplasm Female 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Venous Thromboembolism 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × palbociclib × Clear all
NCT06760637 2026-05-19

FourLight-3

Pfizer

Phase 3 Active not recruiting
1,035 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
46 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡